Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.

ABSTRACT: To clarify the optimal cumulative cisplatin dose (CCD) in locoregionally-advanced nasopharyngel carcinoma (NPC) patients receiving induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT). Using the NPC-specific database from the established big-data intelligence platform at Sun Yat-Sen University Cancer Center, 583 non-disseminated, locoregionally-advanced NPC patients receiving IC plus CCRT were enrolled. Propensity score matching (PSM) analysis was conducted to control for confounding factors. The median CCD was 160 mg/m² after IC (range, 40-300 mg/m² ); only 74 patients (12.7%) achieved CCD >200 mg/m² . Patients receiving >200 mg/m² CCD did not show significantly improved 5-year overall survival (OS) (HR = 1.19; 95% confidence int

SUBMITTER: Lv JW 

PROVIDER: S-EPMC5834779 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature